文献速递甲状腺疾病

碘塞罗宁治疗甲状腺功能减退对癌症与死亡率的影响

Liothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality.
PubMed 文献 · Thyroid · 2021-01-05

瑞典全国登记研究纳入575,461名成人甲状腺激素治疗者,其中11,147人至少三次购买碘塞罗宁(LT3),中位随访8.1年。多变量分析显示LT3使用与乳腺癌发病率、任何癌症发病率、全因死亡率、任何癌症死亡率及乳腺癌死亡率均无增加相关,部分死亡率模型提示LT3使用者死亡率较低,但可能受剂量与健康状况关联影响。

要点

  • LT3使用未增加乳腺癌发病率(HR 0.93,95%CI 0.75-1.15,仅女性)。
  • LT3使用未增加任何癌症发病率(HR 0.97,95%CI 0.87-1.08)。
  • LT3使用者全因死亡率较低(HR 0.69,95%CI 0.61-0.77),但可能为剂量与健康状态关联的假象。

核心结论

  • 与LT4相比,LT3使用未导致乳腺癌发病率、任何癌症发病率、全因死亡率、任何癌症死亡率或乳腺癌死亡率增加。
  • 调整剂量后LT3使用者死亡率较低,可能为剂量与健康状况/诊断之间潜在关联的假象。

研究设计与样本

  • 共575,461人,其中11,147人至少三次购买LT3(包括LT4与LT3联合),中位随访8.1年。
  • 采用Cox回归,时变暴露变量比较LT3使用者与仅LT4使用者,调整年龄、性别、既往甲状腺癌、既往其他癌症、抗甲状腺药物使用、性激素使用及剂量。

主要发现

  • 乳腺癌发病率(仅女性):HR 0.93(95%CI 0.75-1.15)。
  • 任何癌症发病率:HR 0.97(95%CI 0.87-1.08)。
  • 全因死亡率:HR 0.69(95%CI 0.61-0.77)。
  • 任何癌症死亡率:HR 0.78(95%CI 0.62-0.98)。
  • 乳腺癌死亡率(仅女性):HR 0.91(95%CI 0.50-1.66)。

临床怎么用

  • 对于甲状腺功能减退患者,LT3使用未显示增加癌症发病或死亡风险,可结合个体情况考虑。
  • LT3使用者观察到的较低死亡率需谨慎解读,不应归因于LT3本身的保护作用。

局限性

  • 观察性登记研究,可能存在残余混杂,尤其是剂量与健康状态之间的关联。
  • LT3暴露基于购药记录,无法确认实际服药依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The prescription of liothyronine (LT3) to treat hypothyroidism is increasing worldwide; however, the long-term safety of LT3 use has yet to be determined. Previous studies have suggested a possible association between LT3 use and breast cancer. The aim of this study was to examine the effects of LT3 use on cancer incidence and mortality. Methods: Our sample included the full adult population of individuals living in Sweden with at least three purchases of thyroid hormone therapy between July 2005 and December 2017. Individual-level data on drug purchases were linked to registry data on cancer incidence and mortality. There were 575,461 individuals with at least three purchases, of which 11,147 had made at least three purchases of LT3, including combinations of levothyroxine (LT4) and LT3. Individuals were followed for a median follow-up time of 8.1 years. We applied Cox regression with a time-varying exposure variable, comparing LT3 users (individuals with at least three cumulative purchases of LT3) with LT4-only users (the rest). Outcomes included breast cancer incidence, any cancer incidence, all-cause mortality, any cancer mortality, and breast cancer mortality. We adjusted for age, sex, previous thyroid cancer, previous other cancer, use of antithyroid preparations, use of sex hormones, and dose in multivariate analyses. Results: Multivariate analyses produced a hazard ratio of 0.93 (95% confidence interval [0.75-1.15]) for breast cancer incidence (only females), 0.97 (0.87-1.08) for any cancer incidence, 0.69 (0.61-0.77) for all-cause mortality, 0.78 (0.62-0.98) for any cancer mortality, and 0.91 (0.50-1.66) for breast cancer mortality (only females). Conclusions: In this large, Swedish, long-term registry-based study, the use of LT3 did not lead to increased breast cancer incidence, any cancer incidence, all-cause mortality, any cancer mortality, or breast cancer mortality compared with LT4 use. Somewhat surprisingly, there was evidence of lower mortality in LT3 users in models adjusting for dose, potentially an artifact of underlying associations between dose and health status/diagnosis.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Planck T, Hedberg F, Calissendorff J, et al. Liothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality. Thyroid. 2021. PMID: 33040688. doi:10.1089/thy.2020.0388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。